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Abstract
Aim: To estimate the cost-effectiveness of silver dressings using a health economic model based on time-to-wound-healing
in hard-to-heal chronic venous leg ulcers (VLUs).
Background: Chronic venous ulceration affects 1–3% of the adult population and typically has a protracted course of
healing, resulting in considerable costs to the healthcare system. The pathogenesis of VLUs includes excessive and
prolonged inflammation which is often related to critical colonisation and early infection. The use of silver dressings to
control this bioburden and improve wound healing rates remains controversial.
Methods: A decision tree was constructed to evaluate the cost-effectiveness of treatment with silver compared with non-
silver dressings for four weeks in a primary care setting. The outcomes: ‘Healed ulcer’, ‘Healing ulcer’ or ‘No improvement’
were developed, reflecting the relative reduction in ulcer area from baseline to four weeks of treatment. A data set from a
recent meta-analysis, based on four RCTs, was applied to the model.
Results: Treatment with silver dressings for an initial four weeks was found to give a total cost saving (£141.57) compared
with treatment with non-silver dressings. In addition, patients treated with silver dressings had a faster wound closure
compared with those who had been treated with non-silver dressings.
Conclusion: The use of silver dressings improves healing time and can lead to overall cost savings. These results can be used
to guide healthcare decision makers in evaluating the economic aspects of treatment with silver dressings in hard-to-heal
chronic VLUs.
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Introduction
Chronic venous, lower limb ulceration affects 1–3% of the adult
population worldwide [1] and some patients suffer a repeated
cycle of ulceration, healing, and recurrence. These ulcers will take
months to heal despite appropriate treatment, including efficient
venous compression bandage systems [1–3] and have 12-month
recurrence rates between 18% and 28% [4,5]. Ulcer size and ulcer
duration are clearly identified risk factors for a poor healing
prognosis [6]. Venous leg ulcers (VLUs) are also frequently
painful, malodourous, often with moderate to high exudate, and
have a significant negative impact on patients’ quality of life [7,8].
Treatment is associated with considerable costs to healthcare
systems [4]. The underlying pathogenesis of these hard-to-heal
VLUs is complicated by excessive and prolonged inflammation
which is often related to critical colonisation and early localised
infection [9,10]. A heavy bioburden of colonizing microorganisms
in the wound may be one of the most important barriers to wound
closure [11]. Ionized silver (Ag+) has both anti-inflammatory and
antimicrobial properties with a broad spectrum of action [12–14].
The use of silver-releasing dressings to control bioburden and
improve VLU healing rates has been the subject of considerable
debate with diverse conclusions [15–20]. The VULCAN trial
published in 2009 [21] showed no difference in VLU healing rates
over 12 weeks of observation, when comparing treatment with
silver dressings or non-silver containing absorptive dressings.
Following this publication the use of silver was not recommended
because of the associated higher cost [21], but no measurement of
VLU microbial colonisation or the antimicrobial effect of silver
dressings was made in the trial. However, a recent meta-analysis
showed a statistically significant treatment effect, responder rate,
and healing rate in favour of a silver dressing when treating
critically colonised VLU for four weeks compared with non-silver
dressings [22]. The latter results are in accordance with the
guidance of an international consensus group which recommend
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that silver dressings should be used when a VLU becomes
troublesome (hard-to-heal) and critical colonisation is suspected or
has progressed to localised infection [23]. All silver dressings are
only indicated for their effect to reduce critical colonisation; none
are recommended for healing of VLUs when used without other
supportive treatments, and particularly when there are no clinical
signs of progressive colonisation.
The aim of the current study was to estimate the cost-
effectiveness of silver dressings when used according to recom-
mendations [24]. This was undertaken using a health economic
model based on the time-to-wound-healing in hard-to-heal
chronic VLUs which showed signs of critical colonisation or early
localised infection. Evidence of a cost-effective benefit could be
helpful for healthcare decision makers in evaluating the economic
aspects of treatment with silver-releasing dressings.
Methods
Decision Analytic Framework
In order to establish a health economic model a decision
analytic framework (decision tree) was constructed (Figure 1). The
decision tree explored a decision to use silver dressings (‘Silver
treatment’) or non-silver dressings (‘Non-silver treatment’) for four
weeks in a primary care setting. If ulcers did not improve during
this four week period the patients were assumed to have been
referred to specialist care (Figure 1). The model also reflected ulcer
management in primary care where it was assumed that a silver
treatment would be the first type of dressing used for patients with
hard-to-heal VLUs.
During the initial four week period each patient was deemed to
have one of three possible outcomes; complete healing (‘healed
ulcer’), the ulcer may have decreased in size (‘healing ulcer’), be
unchanged or enlarged (‘no improvement’). The proportion of
patients in each outcome category was estimated: the outcome of
‘healed ulcer’ at four weeks was based on the definition of wound
healing [25,26] used in the four clinical trials included in a
published meta-analysis [22]. ‘No improvement’ was defined as
those ulcers with no change or an expanded ulcer area from
baseline to week four of surveillance. Remaining patients had a
decrease in ulcer area but did not have a healed VLU at four
weeks; this group was categorized as having a ‘healing ulcer’ in the
context of the cost calculation. The progression of ulcer healing
after the four week initial treatment could not be estimated directly
from the clinical data set. Hence, a number of simplifying
assumptions were made:
1. Patients who responded to the four weeks treatment were
assumed to have continued treatment with a non-silver
treatment until their ulcer was healed. Time to wound healing
was estimated by linear extrapolation of the ulcer areas at
baseline and at four weeks for each patient in the data set.
2. Patients who did not respond after four weeks treatment were
assumed to have been referred to a wound specialist for wound
assessment and development of a treatment plan. The healing
time for these ulcers was assumed to be the same whether the
patient was started on the silver treatment or the non-silver
treatment, and set equal to the estimated healing time in
patients with improved ulcers at four weeks in the silver
treatment.
Cost of Wound Management
The cost of wound management was assessed from a United
Kingdom (UK) National Health Care perspective for up to one
year after the VLU treatment had started. To estimate the cost of
wound management a number of simplifying assumptions were
made:
1. Ulcer management was assumed to be performed in a primary
care setting.
2. Nurse salary rates were based on that of a community nurse.
3. Dressing costs included the use of an absorbent dressing. Costs
of absorbent dressings were based on 10610 cm sizes, which
are the most commonly used sizes.
4. A hard-to-heal ulcer was assumed to be changed four times a
week and a normally healing ulcer only twice a week.
5. Patients who did not improve at four weeks were referred to a
wound specialist for further investigation. This was modelled as
a ‘‘one off’’ cost, assuming that the patient would be reviewed
by a wound specialist nurse (1 hour appointment including
urine test, Ankle Brachial Pressure Index (ABPI) measurement,
assessment of treatment plan, communication with primary
care nurses, and follow-up).
6. A band 6 nurse salary rate was used for the estimation of the
cost of this visit.
7. 10% of patients attending the wound clinic were assumed to
have been referred for further investigation; in this assumption
to include duplex Doppler scanning.
8. After referral to a wound specialist, patients were treated in
primary care where their VLU was considered to be hard-to-
heal for an additional two weeks (as opposed to the four weeks
treatment with silver). After that the patient would be
considered as having the same healing time as patients treated
with silver.
Figure 1. Framework for health economic model. The patient cohort consisted of 659 patients with hard-to-heal VLUs.
doi:10.1371/journal.pone.0100582.g001
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Table 1 provides an overview of unit cost applied in the cost
estimation.
Data Sources
To estimate the cost of wound management data was sourced
from the clinical trial data in a published meta-analysis [22]. The
data set was based on four RCTs conducted on 685 patients where
the same active silver dressing (Biatain Ag, Coloplast) was
compared with non-silver dressings with respect to relative
reduction in ulcer area at four weeks. The meta-analysis showed
a statistically significant treatment effect (p = 0.0001), responder
rate (p = 0.001) (defined as the proportion of patients with a
relative ulcer area reduction $40% at 4 weeks), and healing rate
(p = 0.002) in favour of the silver dressing. All patients had venous
or mixed aetiology leg ulcers that exhibited delayed healing
(defined as clinical signs of infection (pain, odour, increased
exudate) and/or less than a 20% ulcer size reduction over four
weeks). These ulcers were defined as hard-to-heal VLUs.
Sensitivity Analysis (Tornado Diagram)
The estimation of treatment costs of silver dressings was based
on typical treatment patterns and did not rely on observed health
care utilisation. In order to assess how robust the silver treatment
cost estimates were with respect to the key assumptions and unit
cost established by this model, a univariate sensitivity analysis was
conducted. Each of the unit costs listed in Table 1 was varied by
650%. Dressing change per week was tested in the range 1–3
changes per week (baseline 2 per week) for a normally healing
wound and in the range 3–5 changes per week (baseline 4 per
week). The Tornado diagram (Figure 2) illustrates which model
parameter has the largest impact on estimated differences in
treatment cost.
Statistical Methods
The statistical uncertainty in the estimated cost difference
between the two treatment arms was estimated from the pooled
data set. Using the health economic framework an estimate of
wound management cost was assigned to each patient and 95%
confidence intervals (CI) were calculated for the difference in cost
between the two treatment arms. No statistical test was performed.
Table 1. Unit cost applied in the analyses (£).
Item Value (£) Source
Biatain dressing (10610) 2.35 Drug tariff price. September 2013
Biatain Ag dressing (10610) 7.97 Drug tariff price. September 2013
Primary care visit (incl. transportation, 1 h) 31.00 Cost of Clinical Support Worker Nursing per hour taken from PSSRU 2012 (p.188)
Secondary care
Initial assessment 103.47 NHS reference costs 2012 (outpatient currency code 107; first visit)
Follow-up visit 84.04 NHS reference costs 2012 (outpatient currency code 107; follow-up)
ABPI assessment 29.95 NHS reference costs 2012 (outpatient currency code 182; first visit)
Duplex scan 55.01 Weighted mean from NHS reference costs 2012 (Total HRGs; RA23Z–RA27Z)
doi:10.1371/journal.pone.0100582.t001
Figure 2. Sensitivity analysis. Change in incremental cost (£) per patient (silver treatment versus non-silver treatment) when
changing key assumptions 650%. The figure includes the assumptions that ‘Dressing change per week. Normal wound’; ‘Cost of primary care
visit. Normal wound’; ‘Cost of silver dressing’; have the highest impact on the incremental cost per patient. For example if the ‘cost of silver dressing’
was higher (turquoise bar) the incremental cost per patient would be reduced, nevertheless, even if the price of silver dressing is 50% more expensive
the incremental cost would remain below zero (i.e. be cost-saving).
doi:10.1371/journal.pone.0100582.g002
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Ethic Statement
The study design is based on treatments algorithms, cost
estimations, and analysis of already published data from a meta-
analysis, and therefore no ethics committee approval was relevant
or sought.
Results
Clinical Outcomes
A higher proportion of ulcers treated with silver dressings healed
during the four week period compared with wounds treated with
non-silver dressings (7.6% compared with 3.4%). The proportion
of healing ulcers was also higher in the group treated with silver
compared with non-silver dressings (79.4% compared with 72.1%,
respectively). A lower proportion of patients treated with silver
dressings had no improvement in ulcer area during the four weeks
compared with patients treated with non-silver dressings (13.0%
compared with 24.5%, respectively, Table 2).
The estimated healing time for the VLUs treated with silver
dressings was shorter than the healing time for the non-silver
treatment group with an average of 10.1 weeks compared with
12.8 weeks, respectively, Table 2.
Economic Results
The economic evaluation of the four week silver treatment in
primary care compared with non-silver treatment is shown in
Table 3.
The initial four weeks treatment in primary care was estimated
to be more expensive for the group treated with silver (£623.52)
compared with non-silver treatment (£533.60). Nevertheless, a
higher proportion of patients treated with silver had ulcers with
complete healing or healing ulcers, and therefore the estimated
average time-to-healed wound was lower (13.8 weeks) compared
with non-silver treatment (16.7 weeks). Hence the average total
treatment cost per patient was lower for silver treatment
(£1,326.57) compared with non-silver treatment (£1,468.14) with
a cost saving of £141.57 (Table 3).
The use of a four week silver treatment was considered to be
cost saving because of a shorter time to healing, and fewer patients
requiring referral to specialist care.
In order to assess how robust the silver dressing cost estimate
was, with respect to the key assumptions and unit cost established
by this model, a univariate sensitivity analysis was conducted
(Figure 2). Within the tested range for the modelling parameters
the incremental cost of the silver treatment was below zero (i.e.
cost-saving) (Figure 2). Thus the health economic model seemed to
be robust to modelling assumptions.
Discussion
Venous ulceration with clinical signs of critical colonisation/
local infection, which forms the focus of this study, is of a chronic
nature and therefore can be classified as hard-to-heal. The time
and costs taken by the health care professionals to diagnose, review
and prescribe, when added to the nurse time for wound
management, dressing changes and application of compression
bandaging, is considerable and outweigh the cost of individual
dressings [27,28]. This health economic analysis was developed in
order to estimate the cost-effectiveness of a more expensive silver
dressing compared with a lower-priced non-silver absorbent
dressing, using the best available clinical data [22]. The model
divides the outcomes into three categories (healed, healing, and no
improvement) and the costs of VLU management reflect a UK
National Health Care perspective. Treatment with silver dressings
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for an initial period of four weeks, using the economic model, was
associated with a cost saving (£141.57, CI 95% from 2275.97 to
27.24) compared with the group of patients treated with non-
silver dressings. This was related to a higher healing rate and
shorter time for wound closure (13.8 weeks compared with 16.7
weeks, respectively). A univariate sensitivity analysis on key
assumptions supported these results. Thus, this health economic
analysis seeks to quantify the cost-implications arising from using a
silver dressing by applying a modelling approach.
Furthermore, using a modelling approach may be better than a
prospective study such as the VULCAN trial [21]. The VULCAN
trial has been criticised for being both too broad and using an
irrelevant treatment protocol (heterogeneous use of silver dressings
with varying contents and different release rates of silver ions,
inappropriate long-term use of silver dressings, use of silver
dressings to heal VLUs rather than their use to control bioburden;
and having no clinical or microbiological assessment of bioburden
made) [29]. Hence, any treatment effect found in the VULCAN
trial does not reflect recommended uses of silver dressings by their
manufacturers [30]. Measuring resource utilisation can be
complicated in prospective studies (for example the VULCAN
trial indirectly estimated the cost of dressing use). We have applied
a modelled-cost outcome based on the best available clinical data
consisting of 659 patients with hard-to-heal VLUs with clinical
signs of infection. The patients were treated with a silver dressing
or a non-silver dressing for four weeks [22] and thereby represent
the best option for calculating the cost implication of using silver
dressings appropriately.
Compared with other modelling-based approaches which have
addressed the cost-effectiveness of silver dressings [31] this analysis
included more robust, clinical (pooled) data [22]. In addition, we
have presented the finding from a meta-analysis that silver
dressings do not only save cost because of a shorter time to
healing (as shown in [31]) but also by reducing the number of
patients with no wound closure or enlarging ulcers (unpublished
data); these patients need special attention in clinical practice and
are likely to be costly to manage.
Although the results presented here are not based on
prospectively-collected, resource utilisation data, the findings
indicate that the use of the silver-challenge in hard-to-heal leg
ulcers is cost-saving compared with the use of non-silver dressings.
Limitations of the study: in this health economic model, it was
assumed that all ulcers would eventually heal (based on linear
extrapolation of healing time). However, in reality some ulcers
Table 3: Comparison of cost of wound management (£) using a four week silver treatment compared with non-silver treatment in
primary care.
Patients (%) Resources (weeks) Unit cost Cost per patient (£)
Silver treatment
Initial 4 weeks (primary care) 100 4{ 155.88 £ per week 623.52
Additional treatment in primary care
Healed ulcer 7.6 - 0.00 £ per patient -
Healing ulcers* 79.4 10.1` 66.70 £ per week 534.44
No improvement (referred to specialist) 13.0
Initial assessment/follow-up** 222.96 £ per patient 29.00
Wound management. Complicated wound 2{ 133.40 £ per week 34.71
Wound management. Healing wound*** 12.1` 66.70 £ per week 104.91
Total cost per patient 1,326.57
Average estimated time to healed wound 13.8
Non-silver treatment
Initial 4 weeks (primary care) 100 4{ 133.40 £ per week 533.60
Additional treatment in primary care
Healed ulcer 3.4 - 0.00 £ per patient -
Healing ulcers* 72.1 12.8` 66.70 £ per week 617.19
No improvement (referred to specialist) 24.5
Initial assessment/follow-up** 222.96 £ per patient 54.59
Wound management. Complicated wound 2{ 133.40 £ per week 65.32
Wound management. Healing wound*** 12.1` 66.70 £ per week 197.44
Total cost per patient 1,468.14
Average estimated time to healed wound 16.7
Incremental cost 2141.57
*Based on linear extrapolation of wound closure during first 4 weeks observed in the meta-analysis [22].
**Unit cost of initial assessment/follow up (From Table 1: £103.47 initial assessment + £84.04 follow-up visit + £29.95 ABPI assessment + £5.50 Duplex scan (10% of
patients assumed to be referred to duplex scan)).
***Total healing time was assumed equal to average time to healing in patients with non-expanding wound estimated in the meta-analysis (minimum of healing time
estimated for silver treatment respectively non-silver treatment arm). The split between weeks with complicated wound and normally healing wound was equal in both
silver treatment and non-silver treatment arms.
{High frequency dressing change (4 times/week).
`Low frequency dressing change (2 times/week).
doi:10.1371/journal.pone.0100582.t003
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may become re-infected and progress to more serious infections, or
other complications which could have arisen, and require
additional wound management and care. The clinical data applied
this model was a 4 weeks period of silver treatment; a shorter
challenge period of silver as suggested by the consensus group [23]
or a longer follow up period was not allowed to be entered into the
model.
Conclusion
Based on a health economic model, where clinical data was
sourced from a recently published meta-analysis, it has been
shown that when patients with hard-to-heal VLUs are allocated to
an initial four weeks treatment using silver dressings there can be
associated cost savings (£141.57) compared with patients who are
treated with non-silver dressings. In addition, patients treated with
silver dressings had wound closure approximately 3 weeks before
those patients treated with non-silver dressings. Thus, use of silver
dressings improves healing time in hard-to-heal VLUs and can
lead to overall cost-savings. These results can be used to guide
healthcare decision makers in evaluating the economic aspects of
treatment with silver dressings in hard-to-heal VLUs.
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